Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
Active, not recruiting · Phase 1, Phase 2 · NCT03386513
Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
At a glance
- Research payments reported, 2025
- $181,832
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 179
About the trial
- Sponsor
- AbbVie
- Tested
- IMGN632 (drug)
- Dates
- Started 2018-01-02; completion 2026-12-30
- Results posted
- Yes
This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.
From ClinicalTrials.gov, last updated 2026-09-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $181,832 in research payments for this study in 2025 (30 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Matthew L. Ulrickson, M.D. Hematology & Oncology · Gilbert, AZ
- Ahmed Aribi, MD Hematology · Duarte, CA
- David A. Sallman, M.D. Hematology & Oncology · Tampa, FL
- Daniel J. Deangelo, M.D.,PH.D. Hematology & Oncology · Boston, MA
- Naval G. Daver, MBBS Hematology & Oncology · Houston, TX
- Roland B. Walter, MD PHD Hematology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Moffitt Cancer Center $101,240
- Banner Casa Grande Medical Center, AZ $50,764
- City of Hope National Medical Ctr $24,830
- Fred Hutchinson Cancer Research Ctr $3,318
- Dana-Farber Cancer Institute $840
- Cll Global Research Foundation $840
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.